Denmark Servier’s Estève Speranza outlines the rationale behind the French group’s reorganisation in the Nordic countries, how the global shift towards oncology is playing out in his region, and the Nordics’ relevance to Servier as an innovation hub and home to its antibody centre of excellence. Servier is actively looking…
Switzerland Barbara Fritsche-Surchat outlines Servier’s historic commitment to Switzerland, how the French mid-cap’s global oncology pivot is translating into its Swiss operations, and comments on the evolution of pharma salesforces post-pandemic. Over the years, we have developed a real expertise, predominantly in the cardiovascular field, but we will leverage this…
France The Top 10 pharma companies in the EUR 28.9 million French pharma market in 2019. Homegrown players Sanofi and Servier lead the way, followed by Bayer, Janssen and Mylan. French firms Pierre Fabre, Merial and Ceva Sante also make the list, while AstraZeneca and Teva round out the Top 10.…
France The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19 vaccine as it faces delays with its in-house product and the impact of this on the country’s global scientific standing. Also featured are the rising problem of anti-vaccine sentiment, an exclusive…
Morocco Morocco has made admirable progress in building a national oncology network in recent years, but the country’s cancer patients still face significant challenges in terms of accessing the latest therapies. Here, the Morocco heads of companies with global portfolios of innovative cancer treatments discuss the current situation and how they…
Morocco Multinational pharmaceutical companies are increasingly seeing Morocco as a top manufacturing destination for the African continent. Firms from Europe, Asia-Pacific and the US are investing millions of dollars in bolstering and expanding their drug production facilities in the North African nation thanks to its strategic location, price-competitiveness, and comparatively developed…
Morocco Guillaume Recorbet, general manager of Servier in Morocco, explains Servier’s special status in the Moroccan pharma industry as a multinational company with a historic and extensive manufacturing footprint in the country, shares his three priorities to return the affiliate to the right track after a tough period following price cuts,…
Hungary Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies in Hungary, the generic manufacturer now stands as a fully owned subsidiary of the French Servier Group. However, even today…
China 2009 marks 40 years of China’s liberalization and opening up under then-Premier Deng Xiaoping. Servier China also bears the distinction of having been established that year, celebrating its 40th anniversary in tandem with its host country. The success of Servier China is based on the quality of the people…
France With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a club of companies altogether contributing some EUR 4.5 billion (USD 5 billion) worth of turnover to the home market and…
Thailand PharmaBoardroom last reported on Thailand in 2015, meeting country managers from across the healthcare and life sciences value chain. Here, we chart some of their career progressions since then. Sticking with Servier Guillaume Drianno Guillaume Drianno was Thailand country manager for French firm Servier between 2013 and 2017. Prior…
France The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation. A reform-minded and business-oriented administration under President Emmanuel Macron…
See our Cookie Privacy Policy Here